Scholar

Paul Howard

H-index: 22
Medicine 31%
Public Health 30%

Reposted by: Paul Howard

palliativescot.bsky.social
@drkathrynmannix.bsky.social Edinburgh is famously accessible from the NE of England, & we are always delighted to welcome palliative care people across the border to our conferences. We have a great line up this year, closer & cheaper than London. www.palliativecarescotland.org.uk/content/annu...
paulhoward.bsky.social
Database studies are prone to streaming; i.e. since apixaban is known to carry a lower bleeding risk, more likely to select it if higher bleed risk - can only control for coded risk factors, so some risk factors missed
So it's interesting that they still found apixaban's non-major bleed risk lower
paulhoward.bsky.social
I agree; in UK hospitals I see administration of fluids and drugs delayed for hours in those with difficult veins.
SC would often be a far faster option: fluids, many antibiotics, PPIs, TXA, metoprolol, corticosteroids; the list of drugs given SC grows yearly yet remains little used in UK hospitals

Reposted by: Paul Howard

c0nc0rdance.bsky.social
The idiom "like a moth to the flame" dates to at least the 12th century, to Persian love poem "Layla and Majnun". Shakespeare references it in "Merchant of Venice."

But here's the thing. Moths DON'T fly to flames. And we're just now understanding that.

Let's talk about dorsal light response.
a picture of a mosquito killer hanging from the ceiling with the caption i can 't help it it 's so beautiful
Alt: a picture of a mosquito killer hanging from the ceiling with the caption i can 't help it it 's so beautiful
media.tenor.com
paulhoward.bsky.social
Points I learned were:
1."Normal" levels don't exclude deficiency. NICE suggest MMA if B12 180-350 (indeterminate) but our local haem suggests go straight to trial of Rx (MMA also problematic)
2.Many need maintenance more often than 2-3 monthly, so if Sx recur before next injection, shorten interval
paulhoward.bsky.social
This is a really key point.
E.g studies of "high dose (1mg) B12" are uninterpretable because they use blood levels not symptoms as an outcome (oral replacement can increase blood levels without adequately correcting deficiency).
rachel-h-iow.bsky.social
Because the serum B12 can give surprisingly high levels of false positives (unnecessary painful injections) and false negatives (dangerous symptom progression due to missed diagnosis) neither clinical treatment nor scientific study should rely on blood test results alone (but both usually do).
paulhoward.bsky.social
Hi Calum. Yes, partly that. Partly an "adjusted calcium" type issue (ie B12 levels generally include haptocorrin-bound B12 which is inactive and gets excreted; haptocorrin increases in cancer); partly, like iron, your handling of B12 is altered in inflammation; and partly it's poorly understood
paulhoward.bsky.social
B12 deficiency is also really relevant in palliation. I'm seeing people with fatigue and apparently "normal" B12 levels respond really well to SC B12 replacement (i.e. fatigue in advanced illness but in the absence of cachexia/inflammation). So this thread is really interesting
rachel-h-iow.bsky.social
This afternoon at CluB12 a fascinating overview of the history of B12 deficiency/pernicious anaemia from the amazing Ebba Nexo who has spent her whole career working in this field.

Reposted by: Paul Howard

rachel-h-iow.bsky.social
Because the serum B12 can give surprisingly high levels of false positives (unnecessary painful injections) and false negatives (dangerous symptom progression due to missed diagnosis) neither clinical treatment nor scientific study should rely on blood test results alone (but both usually do).

Reposted by: Paul Howard

rachel-h-iow.bsky.social
This afternoon at CluB12 a fascinating overview of the history of B12 deficiency/pernicious anaemia from the amazing Ebba Nexo who has spent her whole career working in this field.
paulhoward.bsky.social
Here, an RCT showing olanzapine improves cancer-related loss of appetite. That said, like other current appetite stimulant options, it's improving enjoyment of food, but not muscle/strength (here, handgrip strength decreased)

dx.doi.org/10.6004/jncc...
dx.doi.org

Reposted by: Paul Howard

pharmacopalliation.bsky.social
💡 Midazolam is actually water-soluble in its vial, but becomes lipid-soluble once it enters the body.

That’s unusual for a benzodiazepine. The trick lies in its imidazole ring 👇

Reposted by: Paul Howard

magdalenaskipper.bsky.social
“We don’t see an epidemic of autism, but we see an ‘epidemic’ of diagnoses”

A fresh journalistic look at the rise in autism that brings together perspectives from the researchers & the autism community
🧪 #MedSky

@nature.com by @helenpearson.bsky.social

www.nature.com/articles/d41...
Autism is on the rise: what’s really behind the increase?
RFK Jr has vowed to find out what’s responsible, but scientists say he is ignoring answers from decades of research.
www.nature.com

Reposted by: Paul Howard

pharmacopalliation.bsky.social
💊💊ALFENTANIL💊💊
Alfentanil’s pKa ~6.5, much lower than fentanyl (~8.4) or morphine (~8.0)

At physiologic pH (7.4), ~90% of alfentanil exists in the unionised, lipid-soluble form → crosses the blood–brain barrier very rapidly

This explains why alfentanil has the fastest onset of action of any opioid
paulhoward.bsky.social
Hi Sarah, you could get the same outcome with a series of 200mg IM loading doses. I think the key point is that if, say, an initial total of 600mg is sufficient, then the maintenance dose needed is very much less than 800mg/day; or perhaps not necessary at all
paulhoward.bsky.social
Really useful paper. Traditional dosing strategies (200mg IM loading, followed by 800-1200mg/day) don't reflect its half-life. Typical loading doses of around 600mg may not need any follow-on regular dose (or a very-much-less than 800mg/day dose if used)
pallmedpro.bsky.social
Did you know, that the half life of phenobarbitone is an average of 4 days?! The way we use it in palliative care needs to be proportionate, specialist-led, and congruent with known pharmacokinetics. @bmj.com Supportive and Palliative Care has more: spcare.bmj.com/content/earl... #palliativecare
Novel staggered loading of phenobarbitone for refractory seizures and agitation at the end of life
Background Seizures and agitation are distressing symptoms commonly encountered at the end of life and may require treatment with phenobarbitone when standard therapies fail. Current phenobarbitone do...
spcare.bmj.com

Reposted by: Paul Howard

drbenbowers.bsky.social
Reframing resilience in community healthcare. Our latest piece in BJCN
magonlinelibrary.com/doi/abs/10.1...
paulhoward.bsky.social
Elinzanetant, a dual neurokinin 1 and 3 receptor (NK1/NK3) antagonist licenced in UK for peri-menopausal Sx, also now trialed for hot flushes due to endocrine therapy for breastfeeding cancer. Similar trial recruiting for fezolinetant (NK3 antagonist).

www.nejm.org/doi/abs/10.1...
www.nejm.org
donnawakefield.bsky.social
📣Published TODAY 📖
It means so much to me to share our paper on #PalliativeCare & #EoLC for people with pleural #Mesothelioma 🫁 in @palliativemedj.bsky.social

Thank you to @mesouk.bsky.social for funding this research

Please share 🔁
journals.sagepub.com/doi/10.1177/...

References

Fields & subjects

Updated 1m